Association Study between rs10486567, rs13149290, rs1545985 and rs6983267 with Incidence of Prostate Adenocarcinoma Among Iranians

Q4 Pharmacology, Toxicology and Pharmaceutics

Current Pharmacogenomics and Personalized Medicine Pub Date : 2024-07-04 DOI:10.2174/0118756921287724240628080642

Mina Allahverdi, S. Angaji, B. Beikzadeh, Raheleh Roudi

{"title":"Association Study between rs10486567, rs13149290, rs1545985 and rs6983267 with Incidence of Prostate Adenocarcinoma Among Iranians","authors":"Mina Allahverdi, S. Angaji, B. Beikzadeh, Raheleh Roudi","doi":"10.2174/0118756921287724240628080642","DOIUrl":null,"url":null,"abstract":"\n\nProstate cancer is the second most frequent malignancy after lung cancer\namong men, accounting for 7% of new cancers diagnosed around the world (15% in developed regions).\nThis disease has become more prevalent in Iran over the past few decades, moving up the\nrankings from 13th in 1986 to 4th in 2005 and finally reaching third place in a recent study in 2016.\nThe purpose of this study is to investigate the association of rs10486567, rs13149290, rs6983267,\nand rs1545985 with prostate cancer predisposition in the Iranian population. Due to the genetic heterogeneity,\neach of the SNP should be studied separately in various communities.\n\n\n\nThis study was conducted as a case-control study on 200 patients referred\nto Hashminejad Hospital in Tehran. 103 men with prostate adenocarcinoma were selected as case,\nand 97 men with benign prostatic hyperplasia (BPH) were selected as control. In this research, according\nto FAVORGENE-Taiwan extraction kit instructions, genomic DNA was extracted from\nperipheral blood lymphocytesTetra-primer ARMS-PCR method was used for SNP genotyping.\n\n\n\nThe significance level at the first stage was p-value≤0.4. rs10486567 (p-value = 0.802) and\nrs6983267 (p-value = 0.684). Based on the additive and multiplicative genetic model, no association\nof these polymorphisms with prostate adenocarcinoma was observed. As a result, rs10486567\nand rs6983267 were removed at this stage. rs13149290 (p-value=0.4) and rs1545985 (p-value=0.4)\nat this stage were selected for the next stage. At the second stage rs13149290 (p-value=0.043)\nshowed a significant difference in the comparison between the two groups, but this difference was\nnot observed in relation to rs1545985 (p-value=0.392) rs1545985 was not associated with prostate\nadenocarcinoma in the additive genetic model. According to P=0.013 and OR (95% CI) =3.837\n(1.306-11.268), rs13149290 polymorphism is associated with prostate adenocarcinoma in the additive\ngenetic model (TT vs CC).\n\n\n\nAs a result of this study, it was observed that rs13149290 is associated with prostate\ncancer in the Iranian population. Also this polymorphism is associated with Gleason score=7 and\nPSA ≤4. Prostate cancer as an exposure effect is heterogeneous between different PSA levels. It is\nsuggested that this polymorphism be investigated in a larger population and in each ethnic group\nseparately.\n","PeriodicalId":11056,"journal":{"name":"Current Pharmacogenomics and Personalized Medicine","volume":" 16","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Pharmacogenomics and Personalized Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/0118756921287724240628080642","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}

引用次数: 0

Abstract

Prostate cancer is the second most frequent malignancy after lung cancer among men, accounting for 7% of new cancers diagnosed around the world (15% in developed regions). This disease has become more prevalent in Iran over the past few decades, moving up the rankings from 13th in 1986 to 4th in 2005 and finally reaching third place in a recent study in 2016. The purpose of this study is to investigate the association of rs10486567, rs13149290, rs6983267, and rs1545985 with prostate cancer predisposition in the Iranian population. Due to the genetic heterogeneity, each of the SNP should be studied separately in various communities. This study was conducted as a case-control study on 200 patients referred to Hashminejad Hospital in Tehran. 103 men with prostate adenocarcinoma were selected as case, and 97 men with benign prostatic hyperplasia (BPH) were selected as control. In this research, according to FAVORGENE-Taiwan extraction kit instructions, genomic DNA was extracted from peripheral blood lymphocytesTetra-primer ARMS-PCR method was used for SNP genotyping. The significance level at the first stage was p-value≤0.4. rs10486567 (p-value = 0.802) and rs6983267 (p-value = 0.684). Based on the additive and multiplicative genetic model, no association of these polymorphisms with prostate adenocarcinoma was observed. As a result, rs10486567 and rs6983267 were removed at this stage. rs13149290 (p-value=0.4) and rs1545985 (p-value=0.4) at this stage were selected for the next stage. At the second stage rs13149290 (p-value=0.043) showed a significant difference in the comparison between the two groups, but this difference was not observed in relation to rs1545985 (p-value=0.392) rs1545985 was not associated with prostate adenocarcinoma in the additive genetic model. According to P=0.013 and OR (95% CI) =3.837 (1.306-11.268), rs13149290 polymorphism is associated with prostate adenocarcinoma in the additive genetic model (TT vs CC). As a result of this study, it was observed that rs13149290 is associated with prostate cancer in the Iranian population. Also this polymorphism is associated with Gleason score=7 and PSA ≤4. Prostate cancer as an exposure effect is heterogeneous between different PSA levels. It is suggested that this polymorphism be investigated in a larger population and in each ethnic group separately.

查看原文本刊更多论文

rs10486567、rs13149290、rs1545985 和 rs6983267 与伊朗人前列腺癌发病率的关联研究

前列腺癌是仅次于肺癌的男性第二大恶性肿瘤，占全球新诊断癌症的7%（发达地区为15%）。过去几十年来，该疾病在伊朗的发病率越来越高，从1986年的第13位上升到2005年的第4位，并最终在2016年的一项最新研究中跃居第3位。本研究旨在调查伊朗人群中 rs10486567、rs13149290、rs6983267 和 rs1545985 与前列腺癌易感性的关联。由于遗传异质性，每个 SNP 都应在不同群体中分别进行研究。本研究以病例对照的形式对德黑兰 Hashminejad 医院的 200 名转诊患者进行了研究。研究选取了 103 名前列腺腺癌患者作为病例，97 名良性前列腺增生（BPH）患者作为对照。本研究根据 FAVORGENE-Taiwan 提取试剂盒说明书，从外周血淋巴细胞中提取基因组 DNA，采用四引物 ARMS-PCR 方法进行 SNP 基因分型，第一阶段显著性水平为 p-value≤0.4，rs10486567（p-value = 0.802）和rs6983267（p-value = 0.684）。根据加法和乘法遗传模型，没有观察到这些多态性与前列腺癌的关联。因此，本阶段删除了 rs10486567 和 rs6983267，并在下一阶段选择了 rs13149290（p 值=0.4）和 rs1545985（p 值=0.4）。在第二阶段，rs13149290（p-value=0.043）在两组比较中显示出显著差异，但在加性遗传模型中，rs1545985（p-value=0.392）与前列腺癌无关。根据 P=0.013 和 OR (95% CI) =3.837(1.306-11.268)，rs13149290 多态性在加性遗传模型中与前列腺癌相关（TT vs CC）。该研究结果表明，在伊朗人群中，rs13149290 与前列腺癌有关，而且该多态性与 Gleason 评分=7 和 PSA ≤4 有关。前列腺癌作为一种暴露效应，在不同的 PSA 水平之间存在差异。建议对这一多态性在更大的人群中以及在每个种族群体中分别进行研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Pharmacogenomics and Personalized Medicine Pharmacology, Toxicology and Pharmaceutics-Pharmacology

CiteScore

0.40

自引率

0.00%

发文量

期刊介绍： Current Pharmacogenomics and Personalized Medicine (Formerly ‘Current Pharmacogenomics’) Current Pharmacogenomics and Personalized Medicine (CPPM) is an international peer reviewed biomedical journal that publishes expert reviews, and state of the art analyses on all aspects of pharmacogenomics and personalized medicine under a single cover. The CPPM addresses the complex transdisciplinary challenges and promises emerging from the fusion of knowledge domains in therapeutics and diagnostics (i.e., theragnostics). The journal bears in mind the increasingly globalized nature of health research and services.